Holen Sie sich die Stockscreener-App
24.99
5.00%
1.19
Handel nachbörslich:
25.34
0.35
+1.40%
Schlusskurs vom Vortag:
$23.80
Offen:
$24.42
24-Stunden-Volumen:
1.99M
Relative Volume:
1.89
Marktkapitalisierung:
$1.66B
Einnahmen:
$9.98M
Nettoeinkommen (Verlust:
$-154.08M
KGV:
-9.686
EPS:
-2.58
Netto-Cashflow:
$-159.66M
1W Leistung:
+16.56%
1M Leistung:
+9.08%
6M Leistung:
+8.37%
1J Leistung:
-24.91%
1-Tages-Spanne:
$23.93
$25.79
1-Wochen-Bereich:
$19.72
$25.79
52-Wochen-Spanne:
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Firmenname
Celldex Therapeutics Inc
Sektor
Branche
Telefon
908-200-7500
Adresse
53 FRONTAGE ROAD, HAMPTON
Vergleichen Sie CLDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
24.99 | 1.58B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-10-07 | Eingeleitet | Citigroup | Buy |
| 2024-09-30 | Eingeleitet | Goldman | Neutral |
| 2024-09-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Eingeleitet | Stifel | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-20 | Eingeleitet | TD Cowen | Outperform |
| 2023-11-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Eingeleitet | Wells Fargo | Underweight |
| 2021-09-17 | Eingeleitet | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-22 | Eingeleitet | Guggenheim | Buy |
| 2020-02-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-07 | Eingeleitet | Aegis Capital | Buy |
| 2016-03-08 | Herabstufung | Jefferies | Buy → Hold |
| 2016-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2016-03-07 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-08-11 | Bestätigt | Brean Capital | Buy |
| 2015-08-11 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-11 | Bestätigt | ROTH Capital | Buy |
| 2015-06-02 | Bestätigt | WBB Securities | Strong Buy |
| 2014-11-17 | Bestätigt | ROTH Capital | Buy |
| 2014-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2013-07-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-03-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2013-01-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2012-10-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-09-14 | Bestätigt | Cantor Fitzgerald | Buy |
Alle ansehen
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Assessing Jasper Therapeutics' Earnings Miss and Clinical Pipeline Momentum in a High-Risk, High-Reward Biotech Play - AInvest
Applying Wyckoff theory to Celldex Therapeutics Inc. stockTrade Risk Report & Free High Return Stock Watch Alerts - Newser
Celldex Therapeutics Inc.’s volatility index tracking explained2025 Dividend Review & Long-Term Growth Portfolio Plans - Newser
News impact scoring models applied to Celldex Therapeutics Inc.2025 Top Gainers & Weekly High Return Stock Forecasts - Newser
Can Celldex Therapeutics Inc. hit a new high this monthJuly 2025 Intraday Action & Safe Entry Point Alerts - Newser
Buy Signal for Celldex Therapeutics Inc. Stock Key Technical Indicators to WatchMarket Risk Analysis & Verified High Yield Trade Plans - Newser
Trend analysis for Celldex Therapeutics Inc. this weekJuly 2025 Price Swings & Accurate Intraday Trading Signals - Newser
Can trapped investors hope for a rebound in Celldex Therapeutics Inc.Market Activity Report & Fast Exit Strategy with Risk Control - Newser
Is Celldex Therapeutics Inc. trending in predictive chart modelsLow Risk Stock Trade Opportunity Analysis - Newser
Will Celldex Therapeutics Inc. price bounce be sustainablePortfolio Risk Distribution Analysis Tool - Newser
Building trade automation scripts for Celldex Therapeutics Inc.Stock Forecast Tools for Retail Traders - Newser
Is Celldex Therapeutics Inc. stock a good hedge against inflationInstitutional Holding Behavior Pattern Analysis - Newser
How Celldex Therapeutics Inc. stock performs during market volatilityChart-Based Entry Confirmation for Beginners - Newser
Using portfolio simulators with Celldex Therapeutics Inc. includedFree Daily Picks With Predictable Performance - Newser
Can volume confirm reversal in Celldex Therapeutics Inc.AI Enhanced Strategy for Portfolio Growth - Newser
Will Celldex Therapeutics Inc. continue its uptrendTrading Volume Spike and Reversal Analysis - Newser
Published on: 2025-08-10 21:08:39 - Newser
Celldex Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates - MSN
Celldex Therapeutics Q2 2025 Earnings Miss Estimates, Revenue Falls Short at $0.7 Million - AInvest
Celldex's Strong Financial Position and Promising Pipeline Support Buy Rating Despite Risks - AInvest
Celldex Therapeutics 2025 Q2 Earnings Dramatic Loss Widening - AInvest
Celldex reports Q2 EPS (85c), consensus (84c) - TipRanks
Celldex Therapeutics: Navigating Short-Term Losses to Unlock Long-Term Value in a High-Stakes Biotech Play - AInvest
Celldex: Q2 Earnings Snapshot - San Antonio Express-News
Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $700,000 vs. FactSet Est of $1.0M - MarketScreener
Celldex Therapeutics Inc. Charts Flash Early Recovery SignalsLong Hold Safe Return Strategy Reviewed - metal.it
What makes Celldex Therapeutics Inc. stock price move sharplyHigh-yield market plays - Jammu Links News
What drives Celldex Therapeutics Inc. stock priceSuperior return velocity - Jammu Links News
How does Celldex Therapeutics Inc. generate profit in a changing economyExponential return rates - Jammu Links News
Is it the right time to buy Celldex Therapeutics Inc. stockDynamic investment growth - Jammu Links News
What analysts say about Celldex Therapeutics Inc. stockOutstanding capital appreciation - Jammu Links News
What is the dividend policy of Celldex Therapeutics Inc. stockUnprecedented profits - Jammu Links News
What is the risk reward ratio of investing in Celldex Therapeutics Inc. stockTake advantage of unprecedented market momentum - Jammu Links News
Should I hold or sell Celldex Therapeutics Inc. stock in 2025Capitalize on strategic market trends - Jammu Links News
Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):